Showing results (271-280 of 554) with videos related to
Sort By:
Pageof 56
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 4, 2007
Angiopoietin 2 is a potential mediator of high-dose interleukin 2-induced vascular leakDiana C Gallagher, Rupal S Bhatt, Samir M Parikh, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 13, 2008
Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology GroupMichael B Atkins, Jessie Hsu, Sandra Lee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 11, 2002
A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, temozolomide, interleukin 2, and IFN-alpha 2B in patients with metastatic melanomaMichael B Atkins, Jared A Gollob, Jeffrey A Sosman, et al.Journal of Clinical Immunology|November 1, 1986
The development of anti-interleukin-2 antibodies in patients treated with recombinant human interleukin-2 (IL-2)M Allegretta, M B Atkins, R A Dempsey, et al.Journal for Immunotherapy of Cancer|January 30, 2026
Partitioned overall survival: comprehensive analysis of survival states over 4 years in CheckMate 9ER comparing first-line nivolumab plus cabozantinib versus sunitinib in advanced renal cell carcinomaHollis Viray, Charlene M Mantia, Opeyemi A Jegede, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|March 1, 1995
Cryptococcal disease of the CNS in immunocompetent hosts: influence of cryptococcal variety on clinical manifestations and outcomeD H Mitchell, T C Sorrell, A M Allworth, et al.Journal of Clinical Microbiology|September 17, 1999
Multicenter evaluation of the Abbott LCx Mycobacterium tuberculosis ligase chain reaction assayR Lumb, K Davies, D Dawson, et al.Journal of Translational Medicine|July 31, 2009
Phase I/II open-label study of the biologic effects of the interleukin-2 immunocytokine EMD 273063 (hu14.18-IL2) in patients with metastatic malignant melanomaAntoni Ribas, John M Kirkwood, Michael B Atkins, et al.Journal of Immunotherapy (Hagerstown, Md. : 1997)|July 27, 2002
Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancerPaula G Fraenkel, Seward B Rutkove, Jean K Matheson, et al.JAMA Oncology|March 10, 2017
Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized TrialNaomi B Haas, Judith Manola, Janice P Dutcher, et al.Pageof 56